Does antithrombotic therapy improve survival with colorectal cancer?

World Journal of Surgical Oncology

Research

Masatoshi Hashimoto¹  Takashi Hayashi¹  Hideto Ito¹  Keiichi Fujino¹  Kodai Takahashi¹  Hideki Asakawa¹  Kazuhito Mita¹ 

[1] Department of Surgery, New-Tokyo Hospital, 1271 Wanagaya, 270-2232, Matsudo-city, Chiba, Japan;

关键词: Colorectal cancer;    Antithrombotic therapy;    Antiplatelet therapy;   

DOI  :  10.1186/s12957-017-1235-z

 received in 2016-11-14, accepted in 2017-08-05,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundThe study aimed to evaluate the prognosis for patients with colorectal cancer who underwent surgery while receiving antithrombotic therapy (ATT) across all disease stages and for patients at disease stages 0–III.MethodsThis retrospective cohort study included 710 Japanese patients who underwent surgery for colorectal cancer between January 2009 and November 2015 at our institution. Approximately 35% of these patients received ATT. Of these, 199 (28.0%) received antiplatelet therapy, and 76 (10.7%) received anticoagulant therapy. We investigated the prognosis among patients with colorectal cancer receiving ATT, antiplatelet therapy, or anticoagulant therapy in all-stage and stage 0–III cancers.ResultsFor all disease stages combined, no benefit was observed for ATT, antiplatelet therapy, and anticoagulant therapy groups in the overall survival rates (ATT: 87.8 vs. 78.4%, P = 0.23; antiplatelet therapy: 87.8 vs. 78.6%, P = 0.25; and anticoagulant therapy: 92.2 vs. 80.2%, P = 0.26). However, overall survival rates of patients with stage 0–III colorectal cancer undergoing ATT, antiplatelet therapy, and anticoagulant therapy significantly improved. (ATT: 98.5 vs. 92.7%, P = 0.01; antiplatelet therapy: 98.3 vs. 91.1%, P = 0.02; and anticoagulant therapy: 100 vs. 92.1%, P = 0.00).ConclusionReceiving ATT significantly improves overall survival rates in patients with stage 0–III colorectal cancer.

【 授权许可】

CC BY   
© The Author(s). 2017